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Abstract
Background: Given the rapid growth of translational research and personalized healthcare paradigms, the ability
to relate and reason upon networks of bio-molecular and phenotypic variables at various levels of granularity in
order to diagnose, stage and plan treatments for disease states is highly desirable. Numerous techniques exist that
can be used to develop networks of co-expressed or otherwise related genes and clinical features. Such techniques
can also be used to create formalized knowledge collections based upon the information incumbent to ontologies
and domain literature. However, reports of integrative approaches that bridge such networks to create systems-
level models of disease or wellness are notably lacking in the contemporary literature.
Results: In response to the preceding gap in knowledge and practice, we report upon a prototypical series of
experiments that utilize multi-modal approaches to network induction. These experiments are intended to elicit
meaningful and significant biomarker-phenotype complexes spanning multiple levels of granularity. This work has
been performed in the experimental context of a large-scale clinical and basic science data repository maintained
by the National Cancer Institute (NCI) funded Chronic Lymphocytic Leukemia Research Consortium.
Conclusions: Our results indicate that it is computationally tractable to link orthogonal networks of genes, clinical
features, and conceptual knowledge to create multi-dimensional models of interrelated biomarkers and
phenotypes. Further, our results indicate that such systems-level models contain interrelated bio-molecular and
clinical markers capable of supporting hypothesis discovery and testing. Based on such findings, we propose a
conceptual model intended to inform the cross-linkage of the results of such methods. This model has as its aim
the identification of novel and knowledge-anchored biomarker-phenotype complexes.
Background
Translational research is a complex and information-
intensive endeavour, involving numerous actors, tools,
workflows and data types. Several recent reports have
defined the translational research cycle as the bidirec-
tional translation of knowledge and evidence between
the “bench” and the “bedside”. Within this translational
cycle, Sung and colleagues [1] have defined two critical
blockages that exist between basic science discovery and
the design of prospective clinical studies (i.e., T1 block),
and subsequently between the knowledge generated
during clinical studies and the provision of evidence-
based care in the clinical or public health settings (i.e.,
T2 block). A commonly cited phenomenon contributing
to the aforementioned T1 block is the lack of tools cap-
able of enabling the systematic discovery of meaningful
relationships between biomarkers and phenotypes [2].
This issue is particularly pressing given the dimensional-
ity and scale of information generated by modern
sources such as Electronic Health Records (EHRs) and
laboratory instrumentation (e.g., genomic and proteomic
expression profiling). Unfortunately, generalizable
approaches for creating integrative, multi-dimensional
networks spanning a range of granularities from bio-
molecules to clinical phenotypes are largely absent in
the current literature, with the exception of a few
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any medium, provided the original work is properly cited.notable cases [3,4]. It is this gap in knowledge and prac-
tice that motivates the studies and resultant models that
we will report upon in this article.
Given the preceding motivation, in the following sub-
sections we will: 1) review the experimental context for
o u rw o r k ;a n d2 )i n t r o d u c et h r e em e t h o d o l o g i c a l
approaches used in our study to induce and reason
upon multi-dimensional networks of genes, clinical fea-
tures, and conceptual knowledge:
Experimental context
The experimental context for our work stems from a
collaboration with the NCI-funded Chronic Lymphocy-
tic Leukemia Research Consortium (CLL-RC, cll.ucsd.
edu). The CLL-RC coordinates and facilitates basic and
clinical research on the genetic, biochemical and
immunologic bases of Chronic Lymphocytic Leukemia
(CLL), which is the most common adult leukemia in
the United States [5]. The CLL-RC specifically focuses
on the identification of phenotypic ↔ bio-molecular
relationships that may improve clinical diagnosis/sta-
ging and assist in designing personalized treatment
plans and evaluating resultant patient responses. The
consortium utilizes a shared data management plat-
form, known as the CLL-RC Integrated Information
Management System (CIMS), in order to collect, store
and analyze longitudinal bio-molecular and clinical
data. Such data sets are derived from a cohort of over
5,000 patients spanning a time frame of up to eleven
years at the time of this submission. Of note relative
to this experimental context and the methods and
results described in this report, we have utilized three
well-known markers for CLL diagnosis and staging to
verify and validate our findi n g s .S p e c i f i c a l l y ,t h em a r -
kers ZAP70 (zeta-chain associated protein kinase
70kDa) and CD38 (cluster of differentiation 38) are
used, given their previously demonstrated ability to
predict IgVH (immunoglobulin heavy chain variable
region) mutational status, a clinical phenotype com-
monly associated with differentiating between diag-
noses of aggressive versus indolent CLL [5].
Gene co-expression network induction
Gene co-expression networks are established by linking
genes with similar expression profiles in data sets derived
from subjects that demonstrate a shared clinical pheno-
type of interest. The similarity of such expression profiles
are often measured by parameters such as the Pearson
Correlation Coefficient (r,- 1≤ r ≤ 1), with r = 1 imply-
ing perfect correlation and r = -1 being a perfect negative
correlation [6]. Analyses of such similarities in gene
expression are usually employed to identify networks of
genes that may serve to predict disease prognosis or
treatment outcomes [7].
Clinical feature co-expression network induction
Similar to the induction of gene co-expression networks,
clinical co-expression network induction involves the
discovery and quantification of significant motifs of clin-
ical attributes in large-scale data sets [3]. The general
methodological pattern for such approaches involves a
multi-step process of:
￿ Selecting a set of potentially interesting clinical vari-
ables within a large-scale data set, and normalizing or
“binning” their values;
￿ Aggregating variables into a composite data table;
￿ Calculating correlation ranked parameters (e.g.,
Spearman’s rank correlation coefficient) spanning all
potential variable pairings within the data set;
￿ Designating thresholds for correlation metrics to
identify potentially significant correlation motifs;
￿ Visualization and expert validation of the resulting
clinical feature co-expression networks [3].
These methods are intended to facilitate the identifica-
tion of clinical features that exhibit similar co-occurrence
motifs within multi-dimensional data sets, thus providing
the impetus for the retrospective and/or prospective analy-
sis of such patterns and their statistical significance. Of
note, we represent such clinical features as a network con-
struct in order to provide for a computationally tractable
representation. Such a structure can incorporate both
atomic features and the probabilistic relationships that
serve to link such features together. This approach has
been described frequently in the published literature [8,9].
Knowledge discovery in databases
Conceptual knowledge can be defined as a combination
of atomic units of information and the meaningful rela-
tionships among those units [10]. The work described in
this report utilizes a conceptual knowledge acquisition
approach known as conceptual knowledge discovery in
databases (CKDD). Such CKDD methods focus on the
utilization of automated or semi-automated computa-
tional methods to derive knowledge from the contents
of databases [10]. The use of domain-specific knowledge
collections, such as ontologies, is necessary to inform
this knowledge induction process since commonly used
database modelling approaches do not always incorpo-
rate semantic knowledge corresponding to its contents.
This overall approach is the basis for a specific CKDD
methodology known as constructive induction (CI),a si s
illustrated in Figure 1. The network-constructs that
serve to link together variable of interests using CI are
referred to in the remainder of this report as Conceptual
Knowledge Constructs (CKCs).
Results
In the following sub-sections, we will present the results
generated during the course of our multi-methodology
Payne et al. BMC Bioinformatics 2010, 11(Suppl 9):S3
http://www.biomedcentral.com/1471-2105/11/S9/S3
Page 2 of 9study. These results are organized per the phases of our
overall research design, and their interrelationships are
explicitly represented in the illustration of our study
design provided in Figure 2.
Phase 1a: CKE-based network induction
A corpus of 107 data elements was extracted from the
CIMS data dictionary, of which 68 (63.5%) and 39
(36.4%) corresponded to phenotypic and bio-molecular
variable types, respectively. Those data elements were
then mapped to concepts found in SNOMED-CT (Sys-
tematized Nomenclature of Medicine - Clinical Terms)
and the NCI Thesaurus ontologies, using the UMLS
(Unified Medical Language System) Knowledge Source
Server lexical search tool. The initial 107 data elements
mapped to 882 (537 unique) ontology concepts, of
which 455 (51.6%) and 427 (48.4%) corresponded to the
initial phenotypic and bio-molecular concepts respec-
tively. Using the previously described CI method, 5800
CKCs were generated. Five subject matter experts
(SMEs) with expertise in the CLL domain evaluated the
validity (defined as the factual accuracy of the CKC) and
meaningfulness (defined as the ability of the CKC to
inform a novel hypothesis) of a random sample of 66
CKCs, indicating that 24.2%, 65.2%, and 10.6% were
completely valid, partially valid/invalid, and completely
invalid, respectively. The SMEs further evaluated those
CKCs designated as completely valid, and concluded
that 90% were meaningful and could be used to formu-
late a novel hypothesis for further testing.
Phase 1b: Gene co-expression network induction
The GDS1388 and GDS1454 data sets were retrieved
from the Gene Expression Omnibus (GEO) database,
comprising 12,651 probe sets. The results for correla-
tion (Pearson Correlation Coefficient, r) and intersec-
tion analysis as applied to these data sets are
summarized in Table 1. For ZAP70, 38 genes were
present in both gene lists, and similarly, 8 genes were
obtained for CD38. Using the CODENSE (Coherent
Dense Subgraphs) algorithm [11], we identified 45
highly connected co-expression networks. Using itera-
tive analyses, a particularly promising network with 51
genes, including ZAP70 and CD38 was identified. For
the genes in this co-expression network, we compared
their expression levels between the 49 patients without
IgVH mutation and the 51 patients with IgVH muta-
tions as found in the GDS1454 data set. Of note and
as introduced earlier, IgVH mutation status is one of a
small number of well-characterized and prospectively
validated biomarkers for predicting CLL disease pro-
gression [5]. The genes with significant differences
between the two groups were further tested for their
capacity of predicting IgVH mutation status using a
supervised linear classifier and a cross validation with
20% sample holdout. These analyses indicated that the
genes that share the same co-expression network with
ZAP70 identified using the preceding approach are
enriched with genes that show significant differential
expression between the IgVH unmutated and mutated
groups.
Figure 1 Overview of constructive induction (CI) methodology. Note that Concept 2, which is included in the ontology but does not map to
the initial database construct, is used as an intermediate concept to define a triplet known as a conceptual knowledge construct (CKC).
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induction
As is described in our methods, we calculated a 125x125
correlation matrix using a data set corresponding to a
random sample of 1516 patient encounters recorded in
CIMS (where those encounters corresponded to a longi-
tudinal series of events for a given patient). In order to
focus on the highly correlated attributes, we set a
threshold of r≥ 0.95, and generated a clinical attribute
network from those attributes satisfying such criteria.
A histogram representing the distribution of such values
was created and fitted by a straight line in log-log
scale, implying that the induced network is scale-free
(Figure 3). We examined the top ten nodes in our net-
work that exhibited the highest degree of connections.
Interestingly, seven of them are related to common
CLL-related laboratory measurements, including: hemo-
globin, billirubin, creatine, albumin, calcium, red blood
cell count, and alkaline phosphate. The remaining three
nodes are all prognostic markers, including: IgVH
homology and ZAP70 gene expression. When this net-
work was visualized using Pajek (http://pajek.imfm.si/
doku.php), and examined by an SME, it was determined
that within the core network, the majority of the attri-
butes corresponded to clinical phenotypes, cytogenetics,
and participant demographics. In contrast, at the bound-
ary of the core network, the majority of variables corre-
sponded to prognostic markers that served to interface
core nodes with the peripheral nodes. Another interest-
ing observation is that all but one of the attributes
related to quantitative immunophenotyping measure-
ments were in the peripheral areas of the visualization.
Figure 2 Overview of study phases, data/knowledge sources, and outcomes/research products.
Table 1 CD38 and ZAP70 gene list intersections. The
p-value’s reported in this table are generated using a
Fishers exact test
GDS #
1388 1454 Intersection p-value
PCC>0.4 (# of genes) 639 114 8 0.263
CD38
PCC<-0.4 (# of genes) 269 1 0 1
PCC>0.4 (# of genes) 944 55 8 0.0543
ZAP70
PCC<-0.4 (# of genes) 575 124 30 <1e-6
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histogram can be fitted by a straight line (red, R=0.93).
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An SME with over ten years of CLL-related research
experience reviewed and annotated the possible interre-
lationships between the networks generated in Phases
1a-c using the methods previously described, notably
including an inspection of an energy-minimized graph
visualization of the composite network created by the
semantically-anchored union of the three preceding net-
w o r k s( F i g u r e4 ) .T h i sa n a l y s i si n d i c a t e dt h ef o l l o w i n g
two characteristics:
1) Of the variables included in the random sample of
CKCs from phase 1a that were considered both valid
and “meaningful”, there was 100% overlap between the
initial or terminal concepts included in those CKCs and
the concepts included in the top ten clinical nodes iden-
tified in phase 1c; and
2) For each gene identified as part of the same CKCs
identified as being novel and “meaningful”, there was at
least one or more linkages between those genes and
analogous genes included in the co-expression network
generated during phase 1b.
Based upon these findings, our SME hypothesized that
multi-dimensional and clinically relevant complexes of
biomarkers and clinical phenotypes could be generated
through the valid, semantic linkages spanning the three
networks. An exemplary instance of such a “vertical
linkage” is shown in Table 2.
Discussion
As was stated at the outset of this report, the ability to
identify and reason upon complexes of biomarkers and
clinical phenotypes is prototypical of the information
needs incumbent to both translational research and per-
sonalized healthcare. In this report, we have described
the application of three different methods for addressing
such needs, spanning levels of granularity from bio-
molecules to domain knowledge sources, all within a
shared experimental context. We have also presented
preliminary findings, and a heuristically derived model,
for the “vertical” integration of such networks. Such an
integrated network can ultimately be employed to iden-
tify and evaluate higher-order bio-marker-to-phenotype
systems that may have basic science and/or clinical sig-
nificance (Figure 5). However, despite these promising
results, a number of critical limitations should be noted,
including: 1) the demonstration of our methods and
findings relative to a single, disease-focused data set; 2)
the continued absence of automated methods to
instantiate “vertical” linkages, spanning bio-marker and
clinical phenotype networks at various levels of granu-
larity; and 3) the limited number of SMEs engaged in
the validation of our initial results. Of note, relative to
the first of these limitations, is the non-domain specific
nature of the computational methods employed in our
studies. We believe that such methods can be readily
Figure 4 Energy-minimized graph visualization of semantically anchored union of network constructs generated in Phases 1a-1c, with significant
groups of nodes annotated to indicated broad concept classes.
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rent efforts by the authors to verify and validate our
approach to multi-network analyses in a number of
immunologic and musculoskeletal diseases. In light of
the remaining limitations, as part of future efforts in
this area of research, we plan to: 1) implement and eval-
uate a semi-automated knowledge-anchored “vertical”
network integration pipeline; and 2) engage a broader
audience of SMEs in systems-level evaluations of our
results.
Conclusions
Given the results described in this report, we believe
that our initial findings provide the basis for a new,
multi-dimensional approach to the discovery of knowl-
edge-anchored biomarker and clinical phenotype com-
plexes. These complexes have the potential to increase
our understanding of critical disease domains at a com-
prehensive and systems level. Ultimately, the derivation
of these types of systems-level models on a regular basis
is critical to realizing the anticipated benefits of transla-
tional research and personalized medicine.
Methods
The objective of our study was to answer the following
three research questions relative to the results generated
via the use of the three preceding methods as applied to
the CIMS data sets:
￿ Can the results of such methods be combined into an
aggregate construct?
￿ Does such a composite construct provide for the dis-
covery of valid and potentially novel networks in large-
scale translational data sets?
￿ Does such a composite construct include higher-order
complexes of markers spanning a spectrum of granularity
from bio-molecules to clinical phenotypes?
In order to address these questions, we employed a
four-phase approach as illustrated in Figure 2 and
Table 2 Exemplary intersection between gene co-expression, knowledge-anchored, and clinical feature co-expression
networks, as identified during Phase 2
Network Initial Concept Network Path or CKC Terminal Concept
Gene Co-
Expression*
CD8A CD8A↔IL2RB↔ZAP70 ZAP70
Conceptual
Knowledge**
ZAP70 [ZAP70 gene]-gene_plays_role_in_process-[Ligand Binding]-
biological_process_involves_gene_product-[LTB4R protein, human]-
gene_product_expressed_in_tissue-[Lymphoid Tissue]-
is_normal_tissue_origin_of_disease-[Chronic lymphocytic leukaemia refractory]
Chronic lymphocytic
leukemia refractory
Clinical Feature
Co-Expression*
Chronic lymphocytic
leukemia refractory
Chronic lymphocytic leukemia refractory (treatment response) ↔ del(17p13) ↔
Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Heavy Chain
Variable-Region Gene ↔ Lactic acid dehydrogenase raised
Lactic acid
dehydrogenase raised
* Network path; ** CKC (including semantic relationships in italics).
Figure 5 Illustration of heuristically derived conceptual model for multi-dimensional marker complex induction and aggregation.
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and validated the data sets and methods employed dur-
ing the course of several preliminary studies [12-14],
and developed novel methods to integrate and analyze
the results of such approaches:
Phase 1a: CKE-based network induction
In the first phase of our study, a set of data elements
f r o mt h eC I M Sd a t ad i c t i o n a r yw e r es e l e c t e db yt w o
SMEs and utilized for CI analyses, which were imple-
mented using a set of specialized PERL scripts and
leveraged the contents of the UMLS. During this pro-
cess, a novel graph-theoretic technique was devised,
controlling the CI process to ensure that only concepts
with similar levels of semantic “granularity” were
included in resulting CKCs. A random sub-set of these
CKCs was selected, and evaluated by five SMEs to deter-
mine both validity and meaningfulness (e.g., the ability
to inform novel hypotheses). The resulting valid and
meaningful CKCs were aggregated as a graph constructs,
using ontology-anchored relationships between constitu-
ent elements to form a network.
Phase 1b: Gene co-expression network induction
In the second phase of our study, the GEO database was
queried using the phrase “chronic lymphocytic leuke-
mia”. Of the returned data sets, those that did not
include overlapping patient cohorts were selected for
further analysis. Of note, these data sets had already
been normalized, per the conventions imposed by the
GEO repository. Using a MATLAB script and the well-
characterized ZAP70 [5] gene as an “anchor”, r values
were calculated for all possible gene pairs in the preced-
ing data sets. The resulting output file was comprised of
a list containing only those genes found with |r| ≥ 0.4
or higher, a threshold selected based upon current best
practices for such co-expression analyses. For compari-
son purposes, we carried out the same operations using
the similarly well-characterized CD38 marker [5] as an
“anchor”. In both instance, the significance of such co-
expression was measured using a Fishers exact text. To
determine which gene symbols could be found in multi-
ple correlation gene lists, an intersection analysis was
performed using a MATLAB script. Building upon the
results generated using these methods, we again queried
GEO using the phrase “metastatic cancer”, and selected
datasets containing both normal and tumor tissues
obtained from a primary biopsy, resulting in 19 datasets
for different cancers. The r values for every pair of
genes in every dataset were calculated, and filtered using
a threshold set at |r| ≥ 0.75. Subsequently, the
CODENSE algorithm [15] was applied to this data set in
order to construct a network where each edge linking a
pair of genes appeared in at least 4 component datasets.
The network motifs that had a connectivity ratio r >0 . 4
(i.e., given a co-expression network with K nodes and
L edges, r=L /(n(n-1)/2)) were selected for further ana-
lyses [11]. The networks that contained ZAP70 and
CD38 were selected for further analyses in the context
of their ability to predict IgVH mutational status, a clini-
cal phenotype commonly associated with differentiating
between diagnoses of aggressive versus indolent CLL, as
was noted earlier in our report [5].
Phase 1c: Clinical feature co-expression network
induction
A set of 182 clinical variables from the CIMS repository
were selected based upon SME input, and the values
associated with the variables were aggregated into a sin-
gle data table based upon shared temporal relationships
(e.g., each set of variables corresponded to a single
research participant encounter). Each categorical vari-
able was binned per the given categorical responses. In
cases where more than eight individual categories were
present, bins were created for ranges of categories. To
further assist in defining parameters for the data sets,
continuous clinical and laboratory variables were com-
pared to the Ohio State University Medical Center’s
(OSUMC) laboratory and clinical data reference ranges.
I ft h ed a t af i e l dc o r r e s p o nded to an existing OSUMC
reference range, it was used to create bins for below
normal, normal, and above normal. Due to the categori-
z a t i o no ft h ed a t as e tv i at h ep r e v i o u s l yd e s c r i b e db i n -
ning process, we used the Spearman rank correlation
method to calculate the correlation coefficient between
pairs of attributes. We ignored null entries and consid-
ered only non-null pairs of entries in order to find the
correlation between attributes. This analysis yielded a
125x125 correlation matrix. Due to null values and
incomplete entries, there were some cases where only a
few data points (as low as 2) were available to calculate
a correlation. Since this phenomenon could potentially
produce statistically unreliable correlation values, we set
a threshold of 20 as the minimum number of non-null
data points needed to reliably calculate the correlation.
If the number of non-null data points was less than 20,
we designated in our results that no correlation between
that pair of attributes existed. The resulting attribute
network was visualized using the Pajek software pack-
age, with a layout mode selected that embedded the
nodes in a 2D plane with maximal energy preserved.
Phase 2: Heuristic evaluation and model formulation
In our final study phase, we compared and integrated
the findings generated in Phases 1a-c. Specifically, we
executed a breadth-first search of all possible pair-wise
linkages between the network generated in Phase 1a and
those generated in Phases 1b-c, using the contents of
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anchored relationships between vertex pairs (implemen-
ted as a JAVA application, leveraging an RDF [Resource
Description Framework] representation of the networks).
This approach employs both the parent-child and sibling
relationships found in the UMLS to enable the identifi-
cations of high-order relationships between the net-
works. Subsequently, an SME reviewed and annotated
the resulting pair-wise relationships based upon their
perceived validity. A multi-network model, made up of
valid cross-linkages, was then induced and visualized
using the open-source Graphviz (http://www.graphviz.
org) software package. Such a model is intended to aid
in the identification of marker complexes spanning mul-
tiple levels of granularity, an dd e r i v e df r o md i f f e r e n t i a l
methods and knowledge sources.
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